Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David J Riese

Showing results (1-10 of 42) with videos related to

Pageof 5
Sort By:
Expert Opinion on Drug Discovery|May 3, 2011
Ligand-based receptor tyrosine kinase partial agonists: New paradigm for cancer drug discovery?David J Riese
Seminars in Cell & Developmental Biology|March 18, 2014
Epiregulin: roles in normal physiology and cancerDavid J Riese, Richard L Cullum
Growth Factors (Chur, Switzerland)|February 1, 2008
The antibody sc-33040-R fails to specifically recognize phosphorylation of ErbB4 on tyrosine1056Richard M Gallo, David J Riese
Oncology Research|January 26, 2005
secErbB4-26/549 antagonizes ligand-induced ErbB4 tyrosine phosphorylationJennifer L Gilmore, David J Riese
Cellular Signalling|May 30, 2002
ErbB2 and ErbB3 do not quantitatively modulate ligand-induced ErbB4 tyrosine phosphorylationKudsia Feroz, Eric Williams, David J Riese
Frontiers in Pharmacology|December 28, 2020
The Role of the CXCL12/CXCR4/CXCR7 Chemokine Axis in CancerYi Shi, David J Riese, Jianzhong Shen
Bioessays : News and Reviews in Molecular, Cellular and Developmental Biology|May 18, 2007
Mutational activation of ErbB family receptor tyrosine kinases: insights into mechanisms of signal transduction and tumorigenesisDavid J Riese, Richard M Gallo, Jeffrey Settleman
Cell Growth & Differentiation : the Molecular Biology Journal of the American Association for Cancer Research|July 13, 2002
Constitutively active ErbB4 and ErbB2 mutants exhibit distinct biological activitiesDesi J Penington, Ianthe Bryant, David J Riese
The Biochemical Journal|February 1, 2006
The epidermal growth factor receptor (EGFR)-S442F mutant displays increased affinity for neuregulin-2beta and agonist-independent coupling with downstream signalling eventsJennifer L Gilmore, Richard M Gallo, David J Riese
Breast Cancer (Dove Medical Press)|December 25, 2013
EGFR may couple moderate alcohol consumption to increased breast cancer riskChristopher P Mill, Julia A Chester, David J Riese
Pageof 5

Showing results (1-10 of 42) with videos related to

Sort By:
Pageof 5
Expert Opinion on Drug Discovery|May 3, 2011
Ligand-based receptor tyrosine kinase partial agonists: New paradigm for cancer drug discovery?David J Riese
Seminars in Cell & Developmental Biology|March 18, 2014
Epiregulin: roles in normal physiology and cancerDavid J Riese, Richard L Cullum
Growth Factors (Chur, Switzerland)|February 1, 2008
The antibody sc-33040-R fails to specifically recognize phosphorylation of ErbB4 on tyrosine1056Richard M Gallo, David J Riese
Oncology Research|January 26, 2005
secErbB4-26/549 antagonizes ligand-induced ErbB4 tyrosine phosphorylationJennifer L Gilmore, David J Riese
Cellular Signalling|May 30, 2002
ErbB2 and ErbB3 do not quantitatively modulate ligand-induced ErbB4 tyrosine phosphorylationKudsia Feroz, Eric Williams, David J Riese
Frontiers in Pharmacology|December 28, 2020
The Role of the CXCL12/CXCR4/CXCR7 Chemokine Axis in CancerYi Shi, David J Riese, Jianzhong Shen
Bioessays : News and Reviews in Molecular, Cellular and Developmental Biology|May 18, 2007
Mutational activation of ErbB family receptor tyrosine kinases: insights into mechanisms of signal transduction and tumorigenesisDavid J Riese, Richard M Gallo, Jeffrey Settleman
Cell Growth & Differentiation : the Molecular Biology Journal of the American Association for Cancer Research|July 13, 2002
Constitutively active ErbB4 and ErbB2 mutants exhibit distinct biological activitiesDesi J Penington, Ianthe Bryant, David J Riese
The Biochemical Journal|February 1, 2006
The epidermal growth factor receptor (EGFR)-S442F mutant displays increased affinity for neuregulin-2beta and agonist-independent coupling with downstream signalling eventsJennifer L Gilmore, Richard M Gallo, David J Riese
Breast Cancer (Dove Medical Press)|December 25, 2013
EGFR may couple moderate alcohol consumption to increased breast cancer riskChristopher P Mill, Julia A Chester, David J Riese
Pageof 5